AstraZeneca's latest respiratory win could spur Bevespi approvals in China, Japan

26th September 2017 Uncategorised 0

Earlier this month, AstraZeneca rolled out positive results for a LAMA/LABA combo COPD med it hopes to bring to the U.S. market. And now, it’s followed up with positive results for another LAMA/LABA that could help the company gain a respiratory foothold in Asia.

More: AstraZeneca's latest respiratory win could spur Bevespi approvals in China, Japan
Source: fierce